Steglatro Tablet, Film Coated
Product Images NDC 0006-5364

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Steglatro (NDC 0006-5364). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Steglatro 01)

Chemical structure of ertugliflozin, the active ingredient in STEGLATRO tablets. The diagram shows the molecular bonds and chemical groups that compose the ertugliflozin molecule.*

FDA Label Image

Figure 1 (Steglatro 02)

A forest plot chart showing the geometric mean ratio (90% confidence intervals) of area under the curve (AUC) and maximum concentration (Cmax) for different drugs (Sitagliptin, Metformin, Glimepiride, Simvastatin, and Rifampin) relative to ertugliflozin alone. The x-axis represents percentage relative to ertugliflozin, with markers indicating the confidence intervals for each drug and dosing condition.*

FDA Label Image

Figure 2 (Steglatro 03)

A chart showing the geometric mean ratio (90% CI) for AUC and Cmax of multiple drugs (Sitagliptin 100 mg, Metformin 1000 mg, Glimepiride 1 mg, Simvastatin 40 mg, Simvastatin Acid) relative to concomitant medication alone. The data compares these values when all ertugliflozin doses were given as a 15 mg single dose.*

FDA Label Image

Figure 3 (Steglatro 04)

A line graph depicting the percentage mean change from baseline in HbA1c levels over 26 weeks for three groups: placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg. The vertical axis shows HbA1c change (%) while the horizontal axis shows weeks. Data points for each group demonstrate a greater reduction in HbA1c with both ertugliflozin doses compared to placebo over time.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

Steglatro 5 mg (ertugliflozin) film-coated tablets packaging label. The label shows the 5 mg strength prominently in a purple box and includes directions to dispense the accompanying Medication Guide. The label notes the product contains 6.48 mg ertugliflozin L-pyroglutamic acid equivalent to 5 mg ertugliflozin. It is an oral prescription tablet packaged in a bottle of 30 tablets by Merck Sharp & Dohme LLC. Storage instructions and a barcode are also visible.*

FDA Label Image

Principal Display Panel (15 mg Tablet Bottle Label)

Label for STEGLATRO (ertugliflozin) tablets, 15 mg strength. The label shows a triangular, film-coated tablet marked with '702.' It includes barcodes, NDC 0006-5364-03, and indicates a package size of 30 tablets. The labeler is Merck Sharp & Dohme LLC. There is a reserved black encoding area for 2D serialization barcode, serial number, expiry, and lot information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.